Ipca Laboratories Q1 net jumps over two-fold to Rs 145.49 cr

Company had posted a net profit of Rs 71.77 crore for the corresponding period of the previous fiscal

Press Trust of India New Delhi
Last Updated : Jul 31 2014 | 4:53 PM IST
Drug firm Ipca Laboratories today reported over two-fold jump in its standalone net profit to Rs 145.49 crore for the quarter ended June 30, 2014, mainly on account of robust formulations sales.

The company had posted a net profit of Rs 71.77 crore for the corresponding period of the previous fiscal, Ipca Laboratories said in a filing to the BSE.

Standalone total income from operations of the company rose to Rs 935.96 crore for the quarter under consideration from Rs 805.56 crore for the same period a year ago.

Also Read

Total revenue from the formulations business rose to Rs 680.92 crore for the quarter ended June 30, 2014, as against Rs 583.11 crore for the corresponding period of the previous fiscal, Ipca Laboratories said.

Active Pharmaceuticals Ingredients (APIs) also witnessed growth in revenue to Rs 247.28 crore for the first quarter of this fiscal. It was Rs 212.22 crore for the same quarter of the last fiscal, it added.

Shares of Ipca Laboratories were today trading at Rs 712.90 per scrip in the afternoon trade on the BSE, down 0.45 per cent from its previous close.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 31 2014 | 3:42 PM IST

Next Story